PPPaolo Petralia

Paolo Petralia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paolo Petralia has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medicine and humanism in the time of COVID-19. Ethical choices

    by Marco Doldi, Andrea Moscatelli, Angelo Ravelli, Raffaele Spiazzi, Paolo Petralia

    The Covid-19 pandemic has been the most defining event of our era. The world of healthcare has experienced first-hand the dramatic situation of treating patients in the face of the dangers of contagion and limited resources. Difficult choices have everywhere been made alongside ethical reflection. Now that, at least in our part of the world, viral infection seems to be broadly on the decline, there is an urgent need for fresh, anthropological, ethical reflection. It is important to avoid being unprepared in the event of further occasions, but above all, to now think in global terms. This is because the pandemic has forced us to recognise the urgency of building alliance in healthcare and a balanced relationship with the environment.


    • 9 November 2020
      • Vol. 91  (Suppl 13) , e2020018
    Open Access

    Complications related to in vitro reproductive techniques support the implementation of natural procreative technologies

    by Aysha Karim Kiani, Stefano Paolacci, Pietro Scanzano, Sandro Michelini, Natale Capodicasa, Leonardo D’Agruma, Angelantonio Notarangelo, Gerolamo Tonini, Daniela Piccinelli, Kalantary Rad Farshid, et al.

    Infertility affects ~20% of the couples in the world. Assisted reproductive technologies (ARTs) are currently the most common treatment option for infertility. Nevertheless, ARTs may be associated with complications for mothers and/or offspring. Natural procreative technology (NaProTechnology) is a natural treatment which minimizes these risks by seeking to identify the causes of infertility to enable better treatments. This narrative review summarizes the complications related to ARTs and clarifies how the NaProTechnology approach can help ARTs to achieve better results or be used in alternative to ARTs. Data in the literature indicate that NaProTechnology is a natural approach for treating infertility. The percentage of live births obtained by NaProTechnology is similar to that of ARTs. An extensive search for the genetic defects causing infertility or subfertility through genetic testing can help both ARTs and NaProTechnology to achieve successful pregnancies. By discovering the underlying causes of infertility, genetic tests enable better family counseling, like the implications of transmitting risk- and disease-alleles to future generations. (www.actabiomedica.it)


    • 9 November 2020
      • Vol. 91  (Suppl 13) , e2020021
    Open Access

    Prenatal genetic diagnosis: fetal therapy as a possible solution to a positive test

    by Aysha Karim Kiani, Stefano Paolacci, Pietro Scanzano, Sandro Michelini, Natale Capodicasa, Leonardo D’Agruma, Angelantonio Notarangelo, Gerolamo Tonini, Daniela Piccinelli, Kalantary Rad Farshid, et al.

    Fetal abnormalities cause 20% of perinatal deaths. Advances in prenatal genetic and other types of screening offer great opportunities for identifying high risk pregnancies. Through a literature search, here we summarise what are the prenatal diagnostic technique that are being used and how those techniques may allow for prenatal interventions. Next generation sequencing and non-invasive prenatal testing are fundamental for clinical diagnostics because of their sensitivity and accuracy in identifying point mutations, aneuploidies, and microdeletions, respectively. Timely identification of genetic disorders and other fetal abnormalities enables early intervention, such as in-utero gene therapy, fetal drug therapy and prenatal surgery. Prenatal intervention is mainly focused on conditions that may cause death or lifelong disabilities, like spina bifida, congenital diaphragm hernia and sacrococcygeal teratoma; and may be an alternative therapeutic option to termination of pregnancy. However, it is not yet widely available, due to lack of specialized centers. (www.actabiomedica.it)


  • Management Aspects, Cost Analysis and Training

    by Paolo Petralia, Nicolò Maria Buffi, Pasquale Cardone, Ubaldo Rosati, Paola Barabino, Luca Pio, Girolamo Mattioli